ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 108,87
0,21%
Dow Jones
39 671,04
-0,51%
DAX
18 727,48
0,24%
Brent Oil
82,375
1,04%
Bitcoin
69 511,52
0,59%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Indaptus Therapeutics Inc (INDP)

  7. Indaptus Therapeutics Inc (INDP) Actualités

INDP

Indaptus Therapeutics (INDP)

Indaptus Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:INDP
DateHeureSourceTitreSymboleSociété
22/05/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
22/05/202414h00GlobeNewswire Inc.Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid TumorsNASDAQ:INDPIndaptus Therapeutics Inc
08/05/202414h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
08/05/202414h00GlobeNewswire Inc.Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
11/04/202413h30GlobeNewswire Inc.Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
28/03/202413h00GlobeNewswire Inc.Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
25/03/202413h30GlobeNewswire Inc.Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
18/03/202413h00GlobeNewswire Inc.Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024NASDAQ:INDPIndaptus Therapeutics Inc
13/03/202412h30GlobeNewswire Inc.Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
04/03/202413h30GlobeNewswire Inc.Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortNASDAQ:INDPIndaptus Therapeutics Inc
15/02/202414h00GlobeNewswire Inc.Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
08/02/202414h00GlobeNewswire Inc.Indaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsNASDAQ:INDPIndaptus Therapeutics Inc
23/01/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
04/01/202414h00GlobeNewswire Inc.European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202322h01GlobeNewswire Inc.Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
06/11/202314h00GlobeNewswire Inc.Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 StudyNASDAQ:INDPIndaptus Therapeutics Inc
31/10/202314h01GlobeNewswire Inc.Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy MeetingNASDAQ:INDPIndaptus Therapeutics Inc
27/09/202314h00GlobeNewswire Inc.Indaptus Therapeutics to Present at the LD Micro Main Event XVINASDAQ:INDPIndaptus Therapeutics Inc
26/09/202314h00GlobeNewswire Inc.Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023NASDAQ:INDPIndaptus Therapeutics Inc
19/09/202314h00GlobeNewswire Inc.Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
06/09/202314h05GlobeNewswire Inc.Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
14/08/202314h00GlobeNewswire Inc.Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
10/08/202314h45GlobeNewswire Inc.Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
07/08/202314h00GlobeNewswire Inc.Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical OfficerNASDAQ:INDPIndaptus Therapeutics Inc
15/06/202314h00GlobeNewswire Inc.Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
31/05/202314h30GlobeNewswire Inc.Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023NASDAQ:INDPIndaptus Therapeutics Inc
30/05/202322h16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INDPIndaptus Therapeutics Inc
25/05/202322h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INDPIndaptus Therapeutics Inc
11/05/202313h00GlobeNewswire Inc.Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
09/05/202314h00GlobeNewswire Inc.Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy PlatformNASDAQ:INDPIndaptus Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:INDP

Dernières Valeurs Consultées

COIN
ETHUSD
Ethereum
EU
MC
Lvmh Moet Hennessy Louis...
NASDAQ
GOOGL
Alphabet
EU
RNO
Renault
NYSE
JPM
JP Morgan Chase
EU
ML
Michelin
EU
ACA
Credit Agricole
EU
VK
Vallourec
FTSE
UKX
FTSE 100
EU
SGO
Cie de SaintGobain
EU
BNP
BNP Paribas
EU
EN
Bouygues
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
EU
BEL20
Bel 20
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés